1. Introduction
===============

Nucleic acid-based strategies used to block gene expression include RNA decoys and antisense compounds. RNA decoys are oligoribonucleotides that compete for a translational activator or mRNA-stabilizing elements, and cause translation inhibition or mRNA destruction ([@bib4], [@bib23]). Antisense strategies employ various structural types of RNA- or DNA-based oligomers, ribozymes or DNAzymes, and small-interfering RNAs (siRNA). All of these approaches are based on Watson-Crick base-pairing of antisense agent to complementary sequence in the mRNA selected for targeting. To be useful *in vivo* these strategies will likely need to utilize modified nucleic acid backbone structures to provide protection from host nucleases. Additionally, a candidate therapeutic must be able to effectively enter cells of relevant tissues and access target RNA. PMO are structurally similar to single-stranded DNA oligonucleotides, but have a different backbone; a morpholine ring replaces the deoxyribose sugar, and a phosphorodiamidate linkage replaces the phosphodiester linkage of DNA ([Fig. 1](#fig1){ref-type="fig"} ) ([@bib47], [@bib55]). PMOs are uncharged, water-soluble, highly resistant to nuclease degradation ([@bib18]), and are typically synthesized to be approximately 20 bases in length. PMO can bind to target mRNA and prevent translation initiation by steric blockade, which is distinct from the RNase H-dependent mechanism of action induced by antisense structural types based on DNA chemistry ([@bib55]). Additionally, PMO conjugated to small, positively charged peptides have far greater delivery efficiency to cells in culture than non-conjugated PMO ([@bib34], [@bib35]).Fig. 1Structure of P4-PMO and locations of P-PMO targets in KSHV immediately early (IE) and latent transcripts. (A) The deoxyribose and phosphodiester bond of the DNA backbone are replaced by a morpholine ring and a phosphorodiamidate linkage, respectively, in PMO. "B" represents the bases A, G, C, or T. The peptide R~5~F~2~R~4~, designated P4, when present, was covalently conjugated to the 5′ end of PMO. (B) Positions of P-PMO designed against KSHV RTA and LANA transcripts. The arrows and the numbers in bold font above arrows indicate open reading frames. The numbers above the transcript lines indicate nucleotide positions in the KSHV genomic sequence ([@bib45]). The sizes of the latent transcripts are indicated above each line. The predicted splicing events of both IE ([@bib57]) and latent transcripts ([@bib11], [@bib59]) are schematically illustrated.

The sequence-specific antiviral efficacy of PMO compounds in cell culture has been documented with caliciviruses ([@bib53]), Hepatitis C virus RNA ([@bib28]), mouse hepatitis virus ([@bib39]), SARS coronavirus ([@bib38]), Equine arteritis virus ([@bib60]) and several flaviviruses ([@bib10], [@bib21]). PMOs have been extensively used to study gene function in zebrafish developmental embryology, a model with relevance to the study of human diseases ([@bib8], [@bib36], [@bib40], [@bib48]). To our knowledge, the application of PMO-technology against a DNA virus has not yet been reported. In this study, a morpholino antisense approach was utilized to reduce the production of replication and transcription activator (RTA) as well as latency-associated nuclear antigen (LANA) proteins of Kaposi\'s sarcoma-associated herpesvirus (KSHV).

KSHV is a large DNA virus associated with Kaposi\'s sarcoma (KS), a type of skin tumor recognized as the most common malignancy among patients with AIDS. KSHV is also associated with several lymphoproliferative disorders, including primary effusion lymphoma (PEL) and multicentric Castleman\'s disease (MCD) ([@bib5], [@bib7], [@bib51]). Like other herpesviruses, KSHV causes two modes of infection: latent and lytic. In latency, the KSHV genome persists with limited gene expression in host cells ([@bib13], [@bib46]). LANA, encoded by ORF73, has a major role in the maintenance of KSHV latency ([@bib3], [@bib22], [@bib25], [@bib24], [@bib50]). LANA interacts with p53 and represses its transcriptional activity ([@bib14]), targets retinoblastoma-E2F transcriptional regulatory pathway, and transforms primary rat cells in cooperation with the oncogene *Hras* ([@bib41]). LANA also up-regulates the telomerase promoter ([@bib61]) and modulates host cellular gene expression ([@bib1], [@bib43]). Mutagenic disruption of ORF73 can lead to abortive KSHV episome persistence ([@bib63]). When KSHV latency is disrupted the virus switches to a lytic phase in which infectious virions are produced, and then spread from cell to cell. The lytic reactivation of virus replication in PEL cells can be induced by various chemicals, such as the phorbol ester tetradecanoyl phorbol acetate (TPA) and sodium butyrate ([@bib44]). KSHV lytic replication can be divided into immediate-early, early and late stages. A key immediate-early gene, ORF50 encodes RTA, and this protein activates viral lytic gene expression ([@bib57]).

RTA activates downstream viral genes of both early and late kinetic classes, including many cellular homologues and nonstructural genes, such as vIRF-1, homologues of macrophage inflammatory protein I and II, vIL-6, vCyclin, viral G-protein-coupled receptor (GPCR), and a homologue of *Bcl*-2 ([@bib32]). Proinflammatory cytokines are considered to be essential for the development of KSHV-associated malignancies ([@bib12], [@bib32]). In KSHV-infected PEL cells and in KS lesions, a low percentage (\<5%) of cells maintain KSHV lytic replication ([@bib31]). Lytic cycle activation is a pivotal event in the cascade of events involved with KSHV replication. RTA is essential as a controlling factor of viral replication during the lytic phase, and contributes to the development of KSHV-associated diseases. In this report, we demonstrate highly efficient uptake of P-PMO by KSHV-infected BCBL-1 cells, as well as highly effective sequence-specific inhibition of RTA and LANA protein expression. Viral genes characteristically expressed downstream of RTA were also suppressed as a result of specific P-PMO-mediated inhibition.

2. Materials and methods
========================

2.1. Cells and viruses
----------------------

KSHV-infected cells BC-1 (EBV-positive) and BCBL-1 (EBV-negative) were derived from body cavity-based lymphomas ([@bib6], [@bib44]). BJAB is a KSHV- and EBV-negative lymphoma cell line ([@bib30]). All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cell numbers were counted using a hemocytometer and cell viability was assessed by trypan blue exclusion. For induction of KSHV lytic replication, TPA (Sigma, St Louis, MO) was added to the cell growth medium to a final concentration of 20 ng/mL.

2.2. PMO and P-PMO design and synthesis
---------------------------------------

PMO were synthesized and purified at AVI BioPharma Inc. (Corvallis, OR) as previously described ([@bib56]) and were designed to be complementary to specific KSHV RNA sequences. PMO were covalently conjugated at the 5′ end to a peptide, NH~2~-RRRRRFFRRRRC-CONH~2~, designated R~5~F~2~R~4~ ([Fig. 1](#fig1){ref-type="fig"}). The methods of conjugation, purification, and analysis of R~5~F~2~R~4~-PMO (P4-PMO, hereafter referred to as P-PMO) were similar to those described previously ([@bib35]). All PMO-compounds used in this study and their target sites in KSHV, are summarized in [Table 1](#tbl1){ref-type="table"} and depicted in [Fig. 1](#fig1){ref-type="fig"}. Fluorescein was conjugated to the 3′ end of a control PMO sequence in both non-conjugated (PMO-Fl) and peptide-conjugated (P-PMO-Fl) forms (see [Table 1](#tbl1){ref-type="table"}), for assessing PMO uptake by BCBL-1 cells.Table 1P-PMO[a](#tbl1fn1){ref-type="table-fn"} sequences and target sitesP-PMO[a](#tbl1fn1){ref-type="table-fn"} nameP-PMO sequence (5′--3′)P-PMO target site (nucleotide positions)RP1[b](#tbl1fn2){ref-type="table-fn"}GTCATCTTGCGC[CAT]{.ul}TTTTGTGGORF50 translation initiation region (76--98)[c](#tbl1fn3){ref-type="table-fn"}mRP1[d](#tbl1fn4){ref-type="table-fn"}GTCA[A]{.ul}CTT[C]{.ul}CGC[G]{.ul}ATT[A]{.ul}TTGT[C]{.ul}GORF50 translation initiation region (76--98)LP1GC[CAT]{.ul}CCTCGGGAAATCTGGORF73 translation initiation region (127293--127312)[e](#tbl1fn5){ref-type="table-fn"}LP2GACGTGACTGCTTCGTGGCGCA5′UTR of LANA latent transcript (127852--127873)LP3GCGGGCGCTACTCACTGTTTATSplice donor site in 5′UTR of LANA latent transcript (127799--127820)P-PMO-F1[f](#tbl1fn6){ref-type="table-fn"}AGTCTCGACTTGCTACCTCARandom control sequencePMO-F1[f](#tbl1fn6){ref-type="table-fn"}AGTCTCGACTTGCTACCTCARandom control sequenceCP1GATATACACAACACCCAATTRandom control sequence[^1][^2][^3][^4][^5][^6]

2.3. Plasmid construction and cell-free luciferase reporter assay
-----------------------------------------------------------------

Complementary oligonucleotides of ORF50 sequence from bases −22 to +14 relative to the AUG translation initiation codon were synthesized and cloned into a luciferase reporter vector in a manner similar to that described previously ([@bib39]). The inserted 'leader' sequence included the RP1 P-PMO target region, and was cloned upstream of AUG-ablated luciferase sequence in the reporter vector. DNA sequencing was conducted to confirm that the insert sequence was in-frame with the luciferase open reading frame. The plasmid DNA was linearized downstream of the target-luciferase fusion gene and *in vitro* transcription was conducted with MegaScript Kit (Ambion, Austin, TX). Cell-free translation reactions were performed with the Rabbit Reticulocyte Lysate System (Promega, Madison, WI). Different concentrations of RP1 P-PMO were added to translation reactions in order to determine its ability to inhibit luciferase production. LP1, which has no sequence homology with RP1, was included in the assay as a control. Luciferase activity in the cell-free translation reactions was measured using an FLx800 microplate luminometer (Bio-Tek Instruments Inc., Winooski, VT). The relative light units produced by each reaction were normalized to the mean of all control reactions and expressed as percent inhibition of luciferase translation.

2.4. PMO/P-PMO uptake analysis
------------------------------

BCBL-1 cells were counted, pelleted and resuspended in RPMI 1640 medium supplemented with 100 μg/mL bovine serum albumin (BSA). The cells were transferred to 12-well cell culture plates at 10^6^ cells per well immediately before PMO compound application. BCBL-1 cells were incubated in 8 μM PMO-F1 or P-PMO-F1 at 37 °C with gentle shaking for 4 h, after which the cells were pelleted, washed with phosphate-buffered saline (PBS, pH 7.2) to remove free PMO-compound, and then observed under a fluorescence microscope.

For flow cytometry analysis, the PMO/P-PMO-treated BCBL-1 cells were pelleted, fixed with 1% paraformaldehyde in PBS for 15 min at room temperature, and analyzed in the FACSCalibur system using CellQuest software program version 3.3 (BD Biosciences, San Jose, CA). Green fluorescence was measured using a 525 nm band pass filter.

To test whether P-PMO could stably persist in BCBL-1 cells, the cells were cultured in growth medium (RPMI 1640 supplemented with 10% fetal bovine serum), treated with P-PMO-F1 as described above, and harvested at 24, 48 or 72 h for analysis by fluorescence microscopy and flow cytometry.

2.5. P-PMO treatment of KSHV-infected cells
-------------------------------------------

KSHV-infected BC-1 and BCBL-1 cells were counted, pelleted and resuspended in RPMI 1640 medium supplemented with 100 μg/mL BSA. The cells were transferred to a 12-well cell culture plate, at 10^6^ cells per well, immediately before P-PMO treatment. P-PMO were diluted in culture media and added to the cells. Control P-PMO CP1 was included as a negative control. Cells treated with PBS were included as a mock-treatment control. After mixing, the cells were incubated for 4 h at 37 °C. Growth medium supplemented with TPA, at 20 ng/mL, was then added to a final volume of 1.5 mL per well. The cells were incubated for 48 h at 37 °C. Cells and culture supernatants were harvested for further analysis. For time-kinetic analysis, TPA was added to the cells at 0, 0.5, 1, 2, 3, or 4 h after the commencement of P-PMO treatment. Growth medium was added to the cells 4 h after P-PMO treatment.

For LANA P-PMO treatment, the same protocol was followed, but TPA was omitted from the growth medium. Recurrent applications of the LANA P-PMO, at 2-day intervals to BCBL-1 cells, were also tested, as described above.

2.6. Immunofluorescence assay (IFA)
-----------------------------------

IFA was utilized to detect proteins in cells as described previously ([@bib16]). Briefly, cells were pelleted, rinsed in PBS three times, and spotted onto slides. The slides were heat-fixed for 2 h at 56 °C. Polyclonal rabbit anti-RTA antibody was used to detect RTA expression ([@bib62]). Mouse monoclonal antibody against vIRF-1 (a gift from Dr. Keiji Ueda of Osaka University School of Medicine, Japan), mouse monoclonal antibody against a glycoprotein encoded by KSHV ORF-K8.1A, rat anti-LANA monoclonal antibody and polyclonal rabbit anti-vIL-6 antibody (Advanced Biotechnologies Inc., Columbia, MD) were used to detect vIRF-1, K8.1A, LANA, and vIL-6 proteins in the cells, respectively. Goat anti-mouse IgG-fluorescein isothiocynate (FITC), anti-rat IgG-FITC, or anti-rabbit IgG-FITC (Sigma) conjugates were used to identify specific reactions. Stained cells were observed under fluorescence microscopy.

For flow cytometry analysis, cells were fixed in 1% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 5 min at room temperature. The rabbit anti-RTA antibody and goat anti-rabbit IgG-FITC conjugates were used to detect RTA protein. The stained cells were resuspended in PBS and analyzed in the FACSCalibur system (BD Biosciences) as described above. Cells were mock-stained or stained with secondary antibody only when included as negative controls.

2.7. Western blot analysis
--------------------------

RTA protein expression in KSHV-infected cells was identified by Western blot analysis. BCBL-1 cells were lysed and resolved in 12% polyacrylamide gels by SDS-PAGE. The separated proteins were transferred to nitrocellulose membrane and probed with rabbit anti-RTA antiserum. Any specific reaction was detected with goat anti-rabbit IgG conjugated with horseradish peroxidase (Sigma) and the addition of chemiluminescence substrate. Chemiluminiscence signal was collected by a VersaDoc 3000 digital imaging system (Bio-Rad Laboratories, Hercules, CA). Tubulin was detected on the same blot membranes to normalize protein loading in the analysis. Similarly, protein expression from vIRF-1, vIL-6, K8.1A and LANA gene products was detected with the respective antibodies described above. Digital image analyses were conducted using Quantity One software (Version 4.4) (Bio-Rad).

2.8. Cell viability assay
-------------------------

The effect of P-PMO treatment on BCBL-1 cell viability was determined with CellTiter-Blue (Promega). Briefly, BCBL-1 cells were treated with RP1 or CP1 under identical conditions to those described in section 2.5 above, in the absence of virus. Mock-treated cells were included for comparison. BCBL-1 cells without TPA induction were also included as a control. CellTiter-Blue reagent was added and incubated for 1 h at 37 °C. The fluorescence signal was measured with a Synergy HT Multi-Detection Microplate Reader (Bio-Tek).

2.9. Statistical analysis
-------------------------

A single factor ANOVA statistical analysis was conducted to test target protein expression differences between the groups of PMO-treated cells ([@bib54]). A two-tailed *P*-value of less than 0.05 was considered significant.

2.10. DNA isolation and real-time PCR {#sec1}
-------------------------------------

Genomic DNA from cell culture supernatants was isolated using DNAzol (Invitrogen, Carlsbad, CA) and DNA from cells was isolated with Wizard Genomic DNA Purification Kit (Promega). Real-time PCR was conducted with a Chromo 4 Detector system (Bio-Rad) using a primer set (73-RF2, 5′ TGACT TCGCC AACCG TAG 3′ and 73-RR2, 5′ CCTAT GGAGA TGGGA GATGT AG 3′) that was expected to amplify sequence in the ORF73 gene, and iQ SYBR Green Supermix (Bio-Rad). A recombinant plasmid pcDNA3.1/His-ORF73 ([@bib42]) was quantified and used to generate standard curves for the real-time PCR. Cellular β-actin DNA was also amplified in order to assure normalized quantitative PCR detection of KSHV DNA from cells.

3. Results
==========

3.1. Design of P-PMOs against KSHV RTA and LANA transcripts
-----------------------------------------------------------

RP1 P-PMO was designed to base pair with the ORF50/RTA immediate early transcript at translational initiation codon region ([Fig. 1](#fig1){ref-type="fig"}). A control P-PMO, with five-base changes to the RP1 sequence, was also synthesized (mRP1, see [Table 1](#tbl1){ref-type="table"}) to help evaluate if RP1-mediated inhibition of RTA expression was indeed sequence-specific. Three P-PMO were designed to target ORF73/LANA. LP1 is complementary to the LANA translation initiation region ([Fig. 1](#fig1){ref-type="fig"}). LP2 and LP3 P-PMO were designed against separate sequences in the 5′ untranslated region (UTR) of a latent LANA transcript ([Fig. 1](#fig1){ref-type="fig"}). LP3 targets a splice donor site ([@bib11], [@bib59]).

3.2. Cellular uptake of P-PMO by BCBL-1 cells
---------------------------------------------

PMO are neutral in charge, and their conjugation to arginine-rich peptide assists delivery into a variety of cells ([@bib34], [@bib35]); however, there is no literature concerning uptake of PMO compounds by B lymphocytes. In order to investigate this issue, BCBL-1 cells were incubated with PMO-Fl or P-PMO-F1 at a final concentration in the media of 8 μM. After 4 h incubation, microscopy revealed that virtually all of the cells treated with P-PMO-F1 exhibited green fluorescence ([Fig. 2](#fig2){ref-type="fig"}A), while no fluorescence was observed in cells treated with PMO-F1. The results indicate highly efficient uptake of P-PMO-F1, and poor uptake of PMO-Fl, by BCBL-1 cells under these culture conditions.Fig. 2PMO/P-PMO uptake assay in KSHV-infected BCBL-1 cells. BCBL-1 cells were treated for 4 h with 8 μM concentration P-PMO-F1 and photographed under fluorescent microscopy (A). Flow cytometry analysis of BCBL-1 cells treated with P-PMO-Fl or PMO-F1 was conducted (B). BCBL-1 cells were treated with P-PMO-Fl for 4 h and harvested for flow cytometry analysis at 4 (Pink), 24 (Black), 48 (Red) and 72 (Green) h after PMO application. The scale on the *X*-axis represents fluorescence intensity and the scale on *Y*-axis is frequency count. Note the P-PMO uptake and stable presence in BCBL-1 cells at all four time points.

Flow cytometry analysis was conducted to quantify the degree of cellular uptake. A high percentage of BCBL-1 cells treated with P-PMO-F1 for 4 h were fluorescence-positive ([Fig. 2](#fig2){ref-type="fig"}B), while cells treated with PMO-F1 were fluorescence-negative.

To evaluate persistence of P-PMO-F1 after uptake, BCBL-1 cells were treated with P-PMO-F1 for 4 h, rinsed, replenished with media, and harvested 24, 48 and 72 h later for analysis by fluorescence microscopy and flow cytometry. Green fluorescence was still observed in almost all cells at all three time points. Flow cytometry analysis likewise showed that over 95% of the cells had green fluorescence at all three time points ([Fig. 2](#fig2){ref-type="fig"}B). BCBL-1 cells treated with PBS were included as a mock-treatment control, and no fluorescence was observed in these cells at any time point. Green fluorescence in the P-PMO-F1 treated cells was still observed at day 7 after treatment, but showed reduced intensity (data not shown). The reduction in fluorescence intensity may have been due to cell division and/or signal quenching.

3.3. RP1 inhibition of target RNA translation in a cell-free luciferase reporter assay
--------------------------------------------------------------------------------------

Characterization of RP1 P-PMO mediated inhibition of translation was carried out with the use of a rabbit reticulocyte lysate cell-free translation assay system. Binding of RP1 P-PMO to its target in *in vitro* transcribed RNA was expected to reduce translation of the downstream luciferase reporter. Luciferase activity was reduced by RP1 treatment in a dose-responsive manner, with 98% inhibition at 300 nM RP1, in comparison to a mock-treatment control. Identical treatment with LP1 did not have any effect, indicating a sequence-specific mechanism caused the RP1 mediated inhibition ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 3Cell-free luciferase reporter assay. P-PMO was added to in vitro translation reactions containing RNA transcribed from a reporter construct that included RP1 P-PMO target sequence upstream of, and in-frame with, firefly luciferase coding sequence. LP1 P-PMO was included as a negative control. Luciferase activity in the presence of RP1 or CP1 P-PMO is compared, and graphed as the percentage of mock-treated reactions, which was set as 100%. The average of three tests is shown and the error bar represents variation among the experiments.

3.4. P-PMO dose-dependent inhibitory effect on RTA protein expression
---------------------------------------------------------------------

To investigate the ability of RP1 P-PMO to interfere with translation in living cells, we applied it at a concentration of 16 μM to BCBL-1 cells, and determined the effect on RTA protein expression. In untreated, non-induced BCBL-1 cells, less than 1% of cells were RTA-positive, which indicates that a small number of cells have spontaneous KSHV lytic replication, as expected. In untreated cells after TPA induction, approximately 20% of BCBL-1 cells expressed RTA, as detected by IFA ([Fig. 4](#fig4){ref-type="fig"}A). In induced cells, treatment with RP1 resulted in reduction of cells signaling positive for RTA to approximately 5%, compared with approximately 20% of mock-treated or control P-PMO CP1-treated cells ([Fig. 4](#fig4){ref-type="fig"}A).Fig. 4RP1 P-PMO inhibition of RTA protein expression in BCBL-1 cells post TPA induction. (A) Immunofluorescence assay with anti-RTA antibody. Cells were treated with RP1 or CP1 P-PMO (16 μM) as described in text. The cell nuclei were counterstained blue by 4′,6′-diamidino-2-phenylindole (DAPI) in mounting solution (Molecular Probes). The lower image panel was taken from the same observed fields as the upper panel, but with a DAPI filter to reveal all cells. Note the reduction in RTA-positive cells in the RP1-treated sample (TPA + RP1) in comparison to CP1-treated (TPA + CP1) or mock-treated (TPA + No PMO). (B) Western blot analysis showing dose-responsive inhibition of RTA expression. The same blot was incubated with an anti-tubulin antibody as a protein loading control. RTA signal after TPA induction in BCBL-1 cells was reduced with increasing RP1 concentration, while CP1 did not cause a detectable change. Mock-treated cells were included in the experiment for comparison. (C) Quantitative image analysis confirmed the dose-responsive inhibition of RTA expression by RP1. RTA expression in cells treated with P-PMO is shown as a relative percentage to that of the mock-treated control. (D) Flow cytometry analysis. The number of RTA-positive cells after P-PMO treatment is shown as a percentage of the total cells counted. The average of three tests is shown and the error bar represents variation among experiments. The cells treated with RP1 had a significantly lower number of RTA-positive cells (*P* \< 0.001) in comparison to cells CP1- or mock-treated. (E) Treatment of BCBL-1 cells with a 5 base-change mutant form of RP1 (mRP1) yielded no detectable change in RTA expression by Western blot analysis. This experiment was repeated three times and had similar results; a representative experiment is shown.

The inhibitory effect of RP1 on RTA expression was further examined in KSHV-infected BC-1 cells co-infected with EBV. BC-1 cells were treated in the same manner as described above for BCBL-1 cells. IFA results found that in TPA-induced BC-1 cells, RP1 treatment markedly reduced the number of RTA-positive cells compared to mock-treated cells, while CP1 had no effect (data not shown).

In an effort to confirm the IFA observation of RP1-mediated inhibition, Western blot analysis was performed to determine RTA protein levels in the cells after TPA induction and P-PMO treatment. BCBL-1 cells were treated with a series of two-fold dilutions of RP1 or CP1, ranging from 0.125 to 16 μM. Cells treated with PBS were included as a mock treatment control. Total-cell lysates were subjected to SDS-PAGE and Western blot analysis. The blots show that the level of RTA protein expression in TPA-induced BCBL-1 cells was reduced in a dose-responsive manner by RP1 P-PMO ([Fig. 4](#fig4){ref-type="fig"}B), while identical treatment with CP1 P-PMO resulted in no detectable change in RTA expression ([Fig. 4](#fig4){ref-type="fig"}B), confirming the IFA observation. Quantitative digital image analysis revealed that RP1 treatment of TPA-induced BCBL-1 cells inhibited RTA expression up to 91% when compared to mock-treatment ([Fig. 4](#fig4){ref-type="fig"}C). These results further demonstrate that RP1 inhibited RTA protein expression in BCBL-1 cells in a dose-dependent and sequence-specific manner.

Flow cytometry was also conducted, and the results further confirmed the above IFA and Western blot data. BCBL-1 cells were treated with RP1 or CP1 at a concentration of 8 μM. RTA was detected with rabbit anti-RTA antibody. Similar to IFA analysis, less than 1% of non-induced, and approximately 25% of TPA-induced BCBL-1 cells, were RTA-positive. Approximately 7% of induced cells treated with RP1 were RTA-positive, and this number was significantly lower than that in CP1-treated or mock-treated cells (*P*  \< 0.001) ([Fig. 4](#fig4){ref-type="fig"}D). Cells treated with CP1 had the same profile as the mock treatment control.

It has been shown that ORF50/RTA transcription is induced within 4 h of the addition of TPA, and that KSHV early lytic gene transcripts are detectable 8--13 h after TPA induction ([@bib58]). Our results show that RP1 P-PMO can inhibit RTA protein expression when TPA is added 4 h post RP1 P-PMO application. To characterize the kinetics of RP1 activity, TPA was added to cells at 0, 0.5, 1, 2, 3 or 4 h after RP1 P-PMO application. IFA analysis showed that RP1 treatment reduced RTA protein expression at all of these time points (data not shown). A P-PMO with five base-changes in RP1 sequence (mRP1), tested under identical conditions as RP1, had no effect on RTA protein expression ([Fig. 4](#fig4){ref-type="fig"}E), confirming the sequence-specific activity of RP1.

3.5. Effect of RP1 on KSHV lytic replication
--------------------------------------------

Because RTA is an immediate-early gene that plays a key role in activating KSHV lytic replication, inhibition of RTA protein expression may be expected to block KSHV lytic replication. To investigate this possibility, expression of KSHV lytic genes vIL-6, vIRF-1 and a glycoprotein encoded by ORF-K8.1A, were analyzed in RP1-treated BCBL-1 cells by Western blot analysis. In comparison to mock-treated BCBL-1 cells after TPA induction, expression of these lytic genes was decreased in a dose-dependent manner after treatment with RP1 ([Fig. 5](#fig5){ref-type="fig"}A); up to 98% for vIL-6 ([Fig. 5](#fig5){ref-type="fig"}C) and 93% for vIRF-1 ([Fig. 5](#fig5){ref-type="fig"}D). In contrast, the levels of these proteins in cells treated with CP1 did not have any detectable change ([Fig. 5](#fig5){ref-type="fig"}B). These results indicate that inhibition of RTA expression by RP1 resulted in a reduction of KSHV lytic replication.Fig. 5Western blot analysis to evaluate inhibition of expression of KSHV lytic genes downstream from RP1, in RP1-treated BCBL-1 cells. Expression of vIL-6, vIRF-1, and a glycoprotein encoded by ORF-K8.1A in TPA-induced BCBL-1 cells was reduced with increasing RP1 P-PMO concentration (A). CP1 P-PMO did not cause a detectable change (B). Quantitative image analysis confirms the dose-responsive inhibition of vIL-6 (C) and vIRF-1 (D) in the cells treated with RP1 P-PMO in comparison to mock-treated cells.

LANA is a latent gene product that is expressed constitutively in KSHV-infected cells. To determine the effect of RP1 treatment on KSHV latency, Western blot analysis was conducted to detect LANA levels in BCBL-1 cells treated with RP1. No detectable change in signal generated with a LANA antibody was found in RP1-treated cells, in comparison to mock-treated or CP1-treated cells (data not shown).

We also assessed KSHV replication in PEL cells post 16 μM RP1 or mRP1 treatment. Real-time PCR was conducted with intracellular and cell culture supernatant samples, in order to measure viral DNA levels. It is established that addition of TPA to cell culture media leads to the induction of KSHV lytic replication ([@bib44]). In this experiment TPA induction increased the KSHV viral DNA level by 1.84- and 2.75-fold in cells and culture supernatant, respectively ([Fig. 6](#fig6){ref-type="fig"} ). Cells treated with mRP1 had viral DNA levels similar to the background level observed in mock-treated samples. The KSHV viral DNA level post mRP1 treatment was 2.6- and 2.2-fold as high as that post RP1 treatment. This result further demonstrates that RP1 treatment can specifically result in inhibition of KSHV lytic replication.Fig. 6Real-time PCR to assess KSHV viral DNA level in cells (A) and culture supernatants (B). Viral DNA in samples is shown as copies in log 10 value per milliliter. The P-PMO RP1 and mRP1 were used at a concentration of 16 μM. Error bars show variations of three experiments. Real-time PCR was performed as described in Section [2.10](#sec1){ref-type="sec"}.

3.6. Cell viability assay of BCBL-1 cells after RP1 treatment
-------------------------------------------------------------

Cell viability assays were conducted with P-PMO, in order to assess cytotoxicity, and exclude the possibility that reduction of target gene expression in test cells was being misinterpreted. BCBL-1 cells were treated with either RP1 or CP1, at concentrations of 8 and 16 μM, under conditions identical to the above experiments. The cell densities used in the assay were within the linear range of this method of detection by fluorescent intensity. BCBL-1 cells without P-PMO treatment were included as a mock treatment control. Relative percentages of fluorescence intensity were calculated in comparison to the mock-treatment control. The assay was repeated three times and the averages of the percentages were: 103 and 96% for cells treated with 8 and 16 μM RP1, 106 and 107% for cells treated with 8 and 16 μM CP1, and 103% for the non-induced control. These results show that RP1 and CP1 had no detectable cytotoxicity under the conditions used in the experiments in this report.

3.7. The suppression of LANA by P-PMO treatment
-----------------------------------------------

Three P-PMO designed to target LANA were evaluated in BCBL-1 cells. Application of LP1 at 8 μM concentration to BCBL-1 cells had no effect on LANA expression according to IFA and Western blot analysis. Because LANA is constitutively expressed by BCBL-1 cells at high levels, recurrent application of LP1 every 2 days, for a total of 6 days, was tested, but no change in LANA level was detected. To obtain confirmation that the LP1 P-PMO was capable of binding to its target RNA, a cell-free reporter assay with LP1/luciferase RNA, similar to the RP1/luciferase system described above, was conducted. LP1 was found to be effective at inhibiting translation in this reporter system (data not shown). These results suggest that either LP1 was unable to access KSHV target RNA in BCBL-1 cells, or that successful hybridization of LP1 and its target RNA had little biological impact.

Application of LP2 and LP3 at 1 and 8 μM concentrations, to BCBL-1 cells, caused reduction in LANA protein level as detected by IFA and Western blot ([Fig. 7](#fig7){ref-type="fig"} ). IFA showed that three repeated P-PMO treatments to the same BCBL-1 cells, over 2-day intervals, reduced LANA protein expression, while the same recurrent applications of CP1 or mock treatment had no detectable effect ([Fig. 7](#fig7){ref-type="fig"}A). LANA protein levels were also evaluated by Western blot analysis. LANA protein expression was significantly reduced after a three-time treatment with 8 μM LP2 or LP3 ([Fig. 7](#fig7){ref-type="fig"}B), but remained stable in the mock treatment control. Treated with LP2 or LP3 generated over 60% reduction in LANA protein level after the second application and up to 92% reduction after the third application ([Fig. 7](#fig7){ref-type="fig"}C). LP2 appeared to be somewhat more potent than LP3 in the suppression of LANA protein expression in this experiment.Fig. 7Inhibition of LANA expression in BCBL-1 cells. Immunofluorescence assay with anti-LANA antibodies shows LP2 or LP3 inhibits LANA protein expression in BCBL-1 cells (A). BCBL-1 cells were treated with 8 μM LP2, LP3, or CP1 three times at 2 days intervals, as described in text. The cell nuclei were counterstained to blue by DAPI in mounting solution (Molecular Probes). The lower image panel was taken with a DAPI filter from the same fields as the upper panel. Note that LANA-staining is much weaker in cells treated with LP2 or LP3 than in cells treated with CP1 P-PMO, or mock-treatment. Total LANA protein expression was also evaluated by Western blot analysis (B). Total proteins from all three treatments were collected separately and used for Western blot. The number above each lane represents the number of P-PMO applications, at 2-day intervals, to BCBL-1 cells. Quantitative image analysis confirmed the LANA inhibition by LP2 or LP3 after the second and third applications. (C) LANA protein expression in cells treated with LP2 or LP3 is shown as a percentage relative to the mock-treatment control.

4. Discussion
=============

Our study demonstrates that P-PMO can specifically suppress protein expression of KSHV RTA and LANA. RTA is a protein required in the switching process from latency to lytic replication of KSHV ([@bib57]). After RTA expression is initiated, viral proinflammatory cytokines and transforming genes are expressed, and lytic viral replication is activated ([@bib57]). LANA is crucial in maintaining KSHV latency. Thus, control of RTA and LANA protein expression may be an effective strategy to block KSHV replication.

KSHV-infected BCBL-1 cells are difficult to efficiently transfect with common transfection reagents ([@bib27], [@bib26], [@bib64]). A recent report described the transfection efficiency of BCBL-1 cells with Lipofectamine 2000 liposome (Invitrogen) to be approximately 10% ([@bib64]). PMO are non-charged compounds and, therefore, the use of cationic lipids to deliver them cultured cells is ineffective ([@bib17], [@bib33]). The conjugation of arginine-rich peptides to PMO has proven to be an efficient means to deliver PMO into cultured cells. In this study, R~5~F~2~R~4~-PMO were tested for cellular uptake and persistence in BCBL-1 cells. The presence of P-PMO-F1 in treated BCBL-1 cells indicated that R~5~F~2~R~4~ assisted in PMO uptake; as the corresponding PMO-F1 failed in the uptake assay. Flow cytometry analysis confirmed that P-PMO-F1 entered over 95% of the cells. Furthermore, The P-PMO-F1 persisted for one week after a single application. The uptake assays were conducted in the absence of serum in the cell culture media. The R~5~F~2~R~4~-PMO used in this study achieve relatively poor cellular uptake when applied in the presence of serum. There have been recent reports, however, of a peptide-PMO conjugate (RXR)~4~XB-PMO, which is capable of effective delivery into cells in the presence of serum ([@bib10], [@bib37]). Delivery into relevant cells *in vivo* has been a major challenge in the development of nucleic acid-based therapeutic strategies.

To test the efficacy and specificity of P-PMO, we applied them to KSHV-infected BCBL-1 and BC-1 cells in culture. Testing the effect of P-PMO on target protein expression in these cells has distinct relevance to a natural KSHV infection, as these cell lines were derived from patients with PEL. The IFA and Western blotting results demonstrate that RP1 P-PMO is effective in blocking RTA protein expression in BCBL-1 cells in a dose-responsive and sequence-specific manner, as the control P-PMO CP1 and mRP1 had no effect. There remained faint RTA protein expression in BCBL-1 cells treated with 16 μM RP1, which suggests that some cells achieved little or no uptake of P-PMO or that an insufficient quantity of P-PMO made its way into the subcellular locations where RTA mRNA is translated. The above speculation also provides potential explanation for why higher P-PMO concentrations were required in cultured cells than in the cell-free reporter assay to achieve an equivalent degree of translation inhibition.

Our study showed that RP1 P-PMO suppressed RTA protein expression even when TPA induction was conducted at the same time as P-PMO treatment. The inhibition of RTA protein expression was less effective when RP1 was applied after TPA induction. This observation is consistent with a predicted mechanism of P-PMO action, that is, blocking the initiation of RNA translation into protein ([@bib56]).

A cell viability assay indicated that RP1 had no detectable cytotoxicity in the concentration range used in this study, supporting the conclusion that suppression of RTA or other lytic gene expression was due to the sequence-specific nature of P-PMO inhibition of RTA mRNA translation. Application of high concentrations of the P-PMO, however, may have some adverse effect on cells. We observed that the application of 16 μM RP1 for 4 h did result in approximately 5% cell mortality, and that inclusion of BSA relieved this adverse effect.

RP1 P-PMO application to BCBL-1 cells resulted in reduced expression of a series of viral genes: vIL-6, vIRF-1, and ORF-K8.1A; these genes are typically expressed temporally downstream of RTA. KSHV viral DNA levels in intracellular and culture supernatant samples were also reduced. These results demonstrate that KSHV lytic replication was abrogated in BCBL-1 cells after RTA P-PMO application. This pattern of RTA preeminence in the events of lytic progression is consistent with previous publications ([@bib9], [@bib64]). [@bib9] showed that methotrexate, a potent anti-inflammatory agent and an inhibitor of cellular dihydrofolate reductase, reduces the expression of ORF50/RTA and prevents expression of other lytic genes. The mechanism of this action is not known. Zhu et al. showed that a DNA-based external guidance sequence (EGS) that targets RTA mRNA for RNase P-based cleavage was found to be an effective means to suppress KSHV lytic replication in BCBL-1 cells, despite its limited transfection efficiency ([@bib64]). The above studies strongly suggest that RTA is an appropriate target for antiviral therapy.

LP2 and LP3 P-PMO target the 5′UTR of a latent transcript encoding LANA, and were effective at inhibiting LANA protein production, indicating that the target regions of those compounds are essential for translation of the latent transcript. The efficacy of LP3 suggests that it was able to inhibit the 5′UTR splicing event of the 5.7 Kb latent transcript ([Fig. 1](#fig1){ref-type="fig"}), leading to a reduction of 5.4 Kb transcript encoding LANA. Because the latent transcript encoding ORF72/vCyclin and ORF71/vFLIP is spliced from the same latent transcript as LANA ([@bib11], [@bib59]), LP2 and LP3 P-PMO may have the potential to inhibit the translation of these latent transcripts as well.

LP1 was designed against the LANA translational start-site region, but had no detectable suppressive effect on LANA protein expression. We speculate that this target sequence region of the latent LANA transcript may be inaccessible to P-PMO in cells, as the same P-PMO was effective in an *in vitro* translation reporter assay. RNA secondary structure analysis of the latent transcript using an *mfold* program ([@bib66]) revealed that complex secondary structures likely exist in this translational initiation region (data not shown).

Current anti-herpesvirus drugs target the lytic rather than the latent phase, and it has been reported that cidofovir and foscarnet are the most efficient commercially available compounds against KSHV ([@bib20], [@bib29], [@bib49]). Cidofovir and foscarnet have no effect on expression of latent or early lytic genes ([@bib9]), as these drugs are inhibitors of the viral DNA polymerase, and transcription of early lytic genes occurs before DNA replication in KSHV. LANA, RTA, and early lytic genes such as vIL-6 ([@bib2], [@bib19], [@bib52]) and vIRF-1 ([@bib15], [@bib65]) play important roles in KSHV replication and pathogenesis. Blocking expression of these genes, and thereby that of down-stream genes as well, could contribute to the treatment of KSHV-associated malignancies. Antisense P-PMO compounds targeting RTA and LANA may prove to be effective reagents to impede KSHV replication *in vivo*, and warrant further study.
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[^1]: The peptide R~5~F~2~R~4~ (designated 'P4') is conjugated to the 5′ end of all PMO except PMO-Fl.

[^2]: The underlined nucleotides correspond to the AUG translation initiation codon of RTA mRNA.

[^3]: GenBank accession number for the cDNA of RTA (ORF50) mRNA is [AF091350](AF091350).

[^4]: The underlined nucleotides indicate those changed in comparison to the RP1 sequence.

[^5]: GenBank accession number for the KSHV genome sequence is [U75698](U75698). The numbers in parentheses indicate nucleotide positions in the genome.

[^6]: P-PMO-F1 and PMO-F1 were conjugated to carboxy-fluorescein at 3′ end of the PMO.
